Rephonic
Artwork for Hematologic Oncology Update

Hematologic Oncology Update

Dr. Neil Love
Multiple Myeloma
Chronic Lymphocytic Leukemia
CAR T-Cell Therapy
Non-Hodgkin Lymphoma
Follicular Lymphoma
Bispecific Antibodies
Venetoclax
BTK Inhibitors
Clinical Trials
Myelofibrosis
Acute Myeloid Leukemia
Immune Thrombocytopenia
Chronic Myeloid Leukemia
Mantle Cell Lymphoma
Daratumumab
CAR T Therapy
FDA Approval
Diffuse Large B-Cell Lymphoma
Cytokine Release Syndrome
Tyrosine Kinase Inhibitors

Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.

PublishesTwice weeklyEpisodes545Founded18 years ago
Number of ListenersCategories
Health & FitnessScienceMedicine

Listen to this Podcast

Artwork for Hematologic Oncology Update

Latest Episodes

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:

• Introduction (0:00)

• Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple My... more

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:

• Introduction (0:00)

• Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)

• Noncovalent Bruton Tyrosine Kinase Inhibit... more

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:

• Introduction (0:00)

• Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL... more

YouTube

Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.

more

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc Docs
Two Onc DocsSam and Karine
Blood Cancer Talks
Blood Cancer TalksRajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
ASCO Daily News
ASCO Daily NewsAmerican Society of Clinical Oncology (ASCO)
Blood Podcast
Blood PodcastAmerican Society of Hematology
The Hematologist
The HematologistThe Hematologist

Recent Guests

Jennifer Brown
Dr. at Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute
Episode: Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Wojciech Jurczak
Dr. at Marie Curie National Research Institute of Oncology, Krakow
Marie Curie National Research Institute of Oncology
Episode: Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Paul Richardson
Dr. Paul Richardson, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Episode: CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Dr. Paul Richardson
A medical oncologist at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Episode: CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Bijal Shah
Oncologist at Moffitt Cancer Center
Moffitt Cancer Center, Tampa, FL
Episode: CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
Constantine Tam
Professor at Monash University, Melbourne
Monash University
Episode: Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
Hanny Al-Samkari
Medical oncologist discussing ASH papers
Massachusetts General Hospital
Episode: Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr. Hanny Al-Samkari
Medical oncologist discussing ASH 2025 ITP papers
Massachusetts General Hospital, Boston
Episode: Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr. Sagar Lonial
A leading oncologist specializing in multiple myeloma
Winship Cancer Institute of Emory University
Episode: Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review

Host

Dr. Neil Love
Lead interviewer and host across multiple series and episodes, focused on hematology-oncology topics and CME-driven education.

Reviews

4.6 out of 5 stars from 131 ratings
  • A debt of gratitude that cannot be repaid

    That is how I feel about Dr Neil Love and his tireless work in continuing medical education for everyone in the medical field. These podcasts and discussions contained are informative, thought provoking and provide and excellent in depth but quick update in the rapidly ever-changing field of Hematology-Oncology.

    Apple Podcasts
    5
    Bongir
    United States3 years ago
  • Excellent content

    Always informative, always applies to those of us on the ground making difficult daily decisions on management in the community. Often with limited resources.

    Apple Podcasts
    5
    ZomBucker
    United States4 years ago
  • Excellent up to date reviews.

    I

    Apple Podcasts
    5
    IanMack5000
    United States15 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Strong guest expertise and case-driven discussions that translate to clinic work.
Consistently up-to-date with ASH data and real-world takeaways.
High quality, practical updates for everyday decision-making in hematology-oncology.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#12
United Arab Emirates/Science
Apple Podcasts
#147
Finland/Science
Apple Podcasts
#148
South Korea/Science
Apple Podcasts
#175
Saudi Arabia/Science
Apple Podcasts
#175
China/Science
Apple Podcasts
#237
Mexico/Science

Talking Points

Recent interactions between the hosts and their guests.

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Q: How do you decide when to use Iberdermide vs Mezindomide in practice if both show promise in early phase data?
Iberdermide is viewed as ideal for upfront or maintenance settings due to tolerability and potential lower second primary cancer risk, while Mezindomide is targeted for heavily pre-treated relapse-refractory patients; trial designs aim to define sequencing and combinations to maximize patient outcomes.
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Q: I know MRD is a surrogate for PFS and OS, but I'm also interested in how you actually look at MRD. Is it just positive or negative? Or are there different levels of positivity?
MRD interpretation must account for disease heterogeneity and the varying impact of different treatments; MRD correlates with PFS and OS, is particularly robust in newly diagnosed settings, and in relapse-refractory contexts it still serves as a meaningful surrogate, though level and context matter for interpretation.
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Q: If you were starting a patient on Iberdomide, what side effects should we anticipate?
Side effects are generally manageable, with fatigue and cytopenias being the primary concerns; Iberdomide tends to be milder in hematologic suppression and surprisingly free of neuropathy, thromboembolism, or off-target toxicities, making it suitable for upfront and maintenance settings.
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Q: What are the preferred initial strategies for ITP in patients with cancer-related thrombocytopenia and autoimmune components?
First-line approaches remain steroids and IVIG for rapid platelet increases. In patients with autoimmune thyroid disease or other autoimmune contributors, some clinicians consider TPO-RAs or combining targeted agents, especially when steroids are poorly tolerated. The choice depends on bleeding risk, comorbidities, and the patient's oncologic therapy plan.
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Q: How does enalumab compare to rituximab mechanistically and in outcomes?
Enalumab is disease-modifying by targeting B-cell activating factor signaling, whereas rituximab depletes B cells and can increase BAF; in some short-term outcomes Rituximab and enalumab may appear similar, but mechanisms and longer-term effects differ with enalumab potentially offering more durable disease modification.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Hematologic Oncology Update

What is Hematologic Oncology Update about and what kind of topics does it cover?

A clinically focused, expert-driven series that features one-on-one conversations with hematology-oncology specialists. Episodes center on the latest data and practice implications from ASH meetings, pivotal trials, and emerging therapies (BTK inhibitors, CELMoDs, ITP treatments, bispecific antibodies, CAR-T). Real-world considerations— MRD testing, sequencing of therapies, transplant timing, and toxicity management—are threaded through practical case discussions. Listeners can expect in-depth, practice-oriented insights from leading clinicians affiliated with major cancer centers, with a strong emphasis on translating trials into community care. Notably, the format often blends trial design explanations with real-world anecdotes to illustr... more

Where can I find podcast stats for Hematologic Oncology Update?

Rephonic provides a wide range of podcast stats for Hematologic Oncology Update. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Hematologic Oncology Update and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Hematologic Oncology Update get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Hematologic Oncology Update, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Hematologic Oncology Update?

Rephonic provides comprehensive predictive audience data for Hematologic Oncology Update, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Hematologic Oncology Update have?

To see how many followers or subscribers Hematologic Oncology Update has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Hematologic Oncology Update?

These podcasts share a similar audience with Hematologic Oncology Update:

1. Two Onc Docs
2. Blood Cancer Talks
3. ASCO Daily News
4. Blood Podcast
5. The Hematologist

How many episodes of Hematologic Oncology Update are there?

Hematologic Oncology Update launched 18 years ago and published 545 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Hematologic Oncology Update?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Hematologic Oncology Update?

Rephonic pulls ratings and reviews for Hematologic Oncology Update from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Hematologic Oncology Update?

Rephonic provides full transcripts for episodes of Hematologic Oncology Update. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Hematologic Oncology Update?

Recent guests on Hematologic Oncology Update include:

1. Jennifer Brown
2. Wojciech Jurczak
3. Paul Richardson
4. Dr. Paul Richardson
5. Bijal Shah
6. Constantine Tam
7. Hanny Al-Samkari
8. Dr. Hanny Al-Samkari

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days